VivoSeq
Other

Familial Adenomatous Polyposis

32

Pipeline Programs↗

7

Active Trials↗

22

Companies Involved↗

Familial adenomatous polyposis is a moderately active landscape with 32 programs across 22 companies. The most active players are Johnson & Johnson, Recursion Pharmaceuticals Inc., Intercept Pharmaceuticals. 5 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

11/100

Mech. Concentration

13/100

Completion Rate

70/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 1R

Recursion Pharmaceuticals Inc.

1 program

Phase 2I

Intercept Pharmaceuticals

1 program

Phase 2S

Solvay Pharmaceuticals

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2EMD Serono logo

EMD Serono

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

95%

Small molecule

35 of 37 classified programs — the dominant modality here.

5%ALL OTHERSMonoclonal antibody25%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 37 pipeline programs.

Analysis

Trial Status

37

clinical trials

Completed16 · 43%
Unknown status6 · 16%
Withdrawn3 · 8%
Terminated3 · 8%
Recruiting3 · 8%
Active, not recruiting2 · 5%
Other4 · 11%

Clinical Trials

Trial Activity

37 trials

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Recruiting·RRapamycin Holdings Inc.·Phase 3·NCT06950385·168 enrolled
Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis
Recruiting·YYonsei University·Phase 3·NCT06545526·28 enrolled
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
Recruiting·RRecursion Pharmaceuticals Inc.·Phase 1/2·NCT05552755·67 enrolled
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis
Active, not recruiting·SS.L.A. Pharma AG·Phase 3·NCT03806426·204 enrolled
Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Active, not recruiting·RRapamycin Holdings Inc.·Phase 2·NCT04230499·30 enrolled
Safety Study for the Use of Rapamycin in Children With Familial Adenomatous Polyposis
Not yet recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT06308445·25 enrolled
Efficacy of Vitamin B1 in Familial Adenomatous Polyposis Patients.
Enrolling by invitation·SShanghai Zhongshan Hospital·N/A·NCT06649825·10 enrolled
Sirolimus and Familial Adenomatous Polyposis (FAP)
Completed·—·Phase 2·NCT03095703·4 enrolled
Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride
Completed·XXijing Hospital of Digestive Diseases·Phase 2/3·NCT03333265·100 enrolled
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Completed·CCancer Prevention Pharmaceuticals, Inc.·Phase 3·NCT01483144·171 enrolled
Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
Completed·UUniversity Medical Center Groningen·Phase 1·NCT02113202·17 enrolled
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Completed·National Cancer Institute (NCI)·Phase 2·NCT02961374·46 enrolled
The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis
Completed·—·Phase 2·NCT05402891·12 enrolled
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05014360·42 enrolled
Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00685568·22 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)